| 1 |
34983356 | Metainflammation in COVID-19. | 2022 Jan 4 |
2 |
| 2 |
33477294 | COVID-19-The Potential Beneficial Therapeutic Effects of Spironolactone during SARS-CoV-2 Infection. | 2021 Jan 17 |
1 |
| 3 |
33708781 | Effect of Spironolactone on COVID-19 in Patients With Underlying Liver Cirrhosis: A Nationwide Case-Control Study in South Korea. | 2021 |
2 |
| 4 |
32721806 | Spironolactone may provide protection from SARS-CoV-2: Targeting androgens, angiotensin converting enzyme 2 (ACE2), and renin-angiotensin-aldosterone system (RAAS). | 2020 Oct |
4 |
| 5 |
33155953 | [Combination therapy at an early stage of the novel coronavirus infection (COVID-19). Case series and design of the clinical trial "BromhexIne and Spironolactone for CoronŠ°virUs Infection requiring hospiTalization (BISCUIT)"]. | 2020 Sep 7 |
1 |
| 6 |
33278189 | Is Spironolactone the Preferred Renin-Angiotensin-Aldosterone Inhibitor for Protection Against COVID-19? | 2020 Dec 4 |
1 |
| 7 |
31165585 | Both aldosterone and spironolactone can modulate the intracellular ACE/ANG II/AT1 and ACE2/ANG (1-7)/MAS receptor axes in human mesangial cells. | 2019 Jun |
1 |